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3-Methoxybenzamide (1) is a weak inhibitor of the essential bacterial cell division protein FtsZ. Alkyl
derivatives of 1 are potent antistaphylococcal compounds with suboptimal drug-like properties.
Exploration of the structure-activity relationships of analogues of these inhibitors led to the identi-
fication of potent antistaphylococcal compounds with improved pharmaceutical properties.
Introduction
Multidrug-resistant strains of Gram-positive pathogens
have evolved which are especially difficult to eradicate. In
particular, the emergence and spread of multidrug-resistant
Staphylococcus aureus is a serious health concern.
1,2 Subse-
quently,thereisacontinuingneedforalternativeantibacterial
agents, especially with novel mechanisms of action. The inc-
reasing use of methicillin resistant S. aureus screening with
rapiddiagnostics
3 priortoelectivehospital admissions means
that a selective antistaphylococcal agent would be a useful
addition to the clinician’s armory.
Cell division has been of considerable interest to the phar-
maceutical industry as a target because it involves a group of
well-conservedproteinsthatareallessentialfortheviabilityof
a wide range of bacteria, and their activities are distinct from
those of the proteins involved in mammalian cell division.
4,5
FtsZ is an essential guanosine triphosphatase that undergoes
GTP-dependent
a polymerization at midcell and assembles to
formtheZ-ring.Whenbacteriadivide,FtsZrecruitsothercell
division proteins to synthesize the septum that enables the
daughter cells to separate. FtsZ is structurally and function-
ally homologous to mammalian β-tubulin, which has been
successfully exploited for cancer therapy.
6-8 This suggests
that FtsZ may also be amenable to inhibitor development.
Several compounds have been reported to block bacterial
cell division through inhibition of FtsZ.
4,9,10 Many of these
reported inhibitors were explored, and 3-methoxybenzamide
(compound 1) was found to be the most attractive for deve-
lopmentintoanantibacterialagent.Recently,wereportedthe
identification of a potent derivativeof 1, PC190723 (Figure1,
compound 2), that inhibits FtsZ, resulting in enlargement of
thebacterialcells(Figure2) andkillingofstaphylococciinvivo.
11
Theearlystructure-activityrelationships(SAR)leadingto
the synthesis of potent 2,6-difluoro-3-alkyloxybenzamide FtsZ
inhibitors from 1 has been published.
12 These 2,6-difluoro-
3-alkyloxybenzamides are 8000  more potent than 1
12 and
are excellent reagents to explore bacterial cell biology. To be
clinicallyefficacious,acompoundmusthaveappropriatephy-
sicochemical properties
13 so that it is absorbed, distributed,
and not extensively metabolized or rapidly excreted. The 2,6-
difluoro-3-alkyloxybenzamides have suboptimal drug-like
absorption, distribution, metabolism, or excretion (ADME)
properties,sotheobjectivewastoimprovethepharmaceutical
profile of these FtsZ inhibitors while retaining the on-target
antistaphylococcal activity to create molecules suitable for
preclinical development.
TheSARandtheprocessusedtocreate2,acompoundwith
attractive in vivo pharmacology, from the 2,6-difluoro-3-alkyl-
oxybenzamideFtsZinhibitorsthathaveantibacterialactivity,
but suboptimal drug-like properties, are described here.
Chemistry
The routes to the target 3-substituted 2,6-difluoro-benza-
mide analogues are concise, straightforward, and are descri-
bed below. The commercially available 2,6-difluoro-3-meth-
oxybenzamide (3) was demethylated to the phenol (4)v i a
treatment with boron tribromide in dichloromethane. The
synthesis of most final compounds was achieved via alkyla-
tion of 4 with an alkyl halide in the presence of potassium
carbonatewithdimethylformamideassolvent(Schemes1and2).
In the case of compounds 6j and 6k, the alkylation of 4 with
the corresponding alcohols was performed under Mitsunobu
reaction conditions, using triphenyl phosphine and diiso-
propyl azodicarboxylate (DIAD) in tetrahydrofuran (THF)
(Scheme 2).
*To whom correspondence should be addressed. Phone: þ441-
865854700. Fax: þ441865854799. E-mail: d.haydon@biota.com.au.
aAbbreviations: ADME, absorption, distribution, metabolism and
excretion; APCI, atmospheric pressure chemical ionization; AUC, area
under thecurve;BSA,bovineserumalbumin;CFU, colonyforming units;
DIAD, diisopropyl azodicarboxylate; DMF, dimethylformamide;
DMSO, dimethyl sulfoxide;ESI, electrospray ionization; GTP, guanosine
triphosphate; HPLC, high pressure liquid chromatography; IP, intraper-
itoneal; IV, intravenous; LC, liquid chromatography; MIC, minimal
inhibitory concentration; MS, mass spectrometry; NMR, nuclear mag-
netic resonance; PO, per oral; PK, pharmacokinetics; Rt, retention time;
SAR, structure-activity relationship; SC, subcutaneous; THF, tetrahy-
drofuran; TLC, thin layer chromatography; UV, ultraviolet.3928 Journal of Medicinal Chemistry, 2010, Vol. 53, No. 10 Haydon et al.
A subseries based on the 5-substituted benzothiazol-2-yl
methoxy group was accessed by alkylation with a wide range
of 5-substituted-2-halomethyl-benzothiazoles (Scheme 3).
Further analogues were accessed by standard modification
of several 5-position substituents.
Similarly, a small series of substituted thiazolopyridines
wasac cesse dbyal kylati onw it hsubs tit ut edhalome th yl -t hiaz o-
lopyridines and subsequent standard modification (Scheme 6).
For the isomeric 4- and 6-substituted subseries of ben-
zothiazoles, a different approach was used if the suitably
substituted 2-halomethyl-benzothiazole was not available.
3-(Cyanomethoxy)-2,6-difluorobenzamide (19)w a sp r e p a r e d
via alkylation of 4 with chloroacetonitrile and served as a
common intermediate for the synthesis of compounds 22a-e
(Scheme 4). The 2-amino-1,3-benzothiazoles (20a-e)w e r e
converted to the required amino thiols (21a-e)b yr e f l u x i n g
with KOH in aqueous 2-methoxyethanol. These in turn were
condensed with 19 in EtOH at 120-150 C to afford the
desired 4-, 6- and 7-substituted benzothiazoles 22a-e.
Results and Discussion
Thebiologicalactivitiesofthecompoundsweredetermined
by measuring the minimal inhibitory concentrations (MICs)
againstS.aureusATCC29213andbymorphometricanalysis
usinglightmicroscopytodetermineon-targetactivity,expres-
sedbyballooningofthecocci.
11,14InlinewithCLSIapproved
standards, the reproducibility of the MIC test is within one
2-fold dilution of the actual end point.
16 On-target activity
was substantiated for selected compounds by generating
compound-resistant strains; in all cases, a mutation was iden-
tified in the ftsZ gene (data not shown). Selected compounds
with a suitable level of on-target activity were screened
through a panel of assays to determine their in vitro ADME
properties. Compounds with drug-like in vitro ADME pro-
files were then characterized in vivo.
To improve the pharmaceutical properties of the 2,6-di-
fluoro-3-alkyloxybenzamideFtsZinhibitors,a seriesofmole-
cules where the alkyl substituent was replaced with a hetero-
cycle, were synthesized (Scheme 2). Approximately 60 of this
type of molecule were synthesized from commercial build-
ing blocks where the molecular weight of R
1 was in the 100-
200 Da range. Replacing the alkyl substituent with such
heterocycles was designed to reduce the log P, the number
of rotatable bonds, and the plasma protein binding of the
molecule as well as to introduce the potential for additional
hydrogen bonding to the FtsZ protein.
TheantibacterialactivityagainstS.aureusandinhibitionof
cell division for a selection of this series of 3-substituted 2,6-
difluorobenzamides(compounds6a-k)ispresentedinTable1.
Several methoxy-linked heterocyclic derivatives demonstrated
potent antistaphylococcal activity mediated through inhibition
of cell division. The most potent of these, a benzothiazole
compound 6g, was selected for additional exploration of the
SAR. Analogues with substitutions in each of the available
positions of the benzothiazole were prepared (Schemes 3, 4, 5).
This series of substituted benzothiazoles were tested for
inhibition of cell division and antibacterial activity against
S. aureus (Table 2). The presence of a chloro substitution in
the4-,6-,or7-positionofthebenzothiazole(compounds 22a,
22b,a n d24e) resulted in active compounds but with reduced
Figure 1. Design of analogues leading toward 2.
Figure 2. Electron micrographs of S. aureus showing cell enlarge-
ment following treatment with compound 2. Cells of S. aureus
ATCC 29213 were cultured (3 h) in the absence (A) or presence
(B) of 2 μg/mL of compound 2 and analyzed by electron micro-
scopy. S. aureus balloons in response to exposure with cell division
inhibitors. Scale bars = 0.5 μm.
Scheme 1. General Synthetic Scheme
a
aReagents and conditions: (i) demethylation: BBr3,C H 2Cl2;( i i )a l k y l -
ationofphenolusingalkyl halides; (iii) alkylationofphenol viaMitsunobu
reaction.
Scheme 2. Alkylation of 2,6-Difluoro-3-hydoxybenzamide 4
Using Alkyl Halides (ii; 5a-i) or via Mitsunobu Reaction
(iii; 5j-k)
a
aReagents: (ii) K2CO3, DMF; (iii) triphenylphosphine, diisopropyl
azodicarboxylate, triethylamine, THF.Article Journal of Medicinal Chemistry, 2010, Vol. 53, No. 10 3929
antibacterial activity and potency in the cell division assay.
Similarly, 4- and 5-methyl as well as 4-methoxy substitutions
of the benzothiazole (compounds 22c, 8f,a n d25) resulted
in less potent but active analogues. One compound, with a
5-methoxy substitution (8h), retained similar activity to the
unsubstituted benzothiazole. From this set of substituted
Scheme 3. Synthesis of 5-Substituted Benzothiazole Derivatives by Alkylation of 2,6-Difluoro-3-hydoxybenzamide (4) Using Alkyl
Halides (7a-7j)
a
aReagents: (i) BBr3,C H 2Cl2; (ii) K2CO3, DMF; (iv) SnCl232H2O, EtOH, reflux; (v) allyltributyltin, tetrakis(triphenylphosphine)palladium(0),
DMF; (vi) Pd-C, MeOH; (vii) bispinacolatodiboron, KOAc, Pd2(dba)3, tricyclohexylphosphine, 1,4-dioxane; (viii) 2-iodoimidazole, dichlorobis-
(triphenylphosphine)palladium(II),K3PO4,DMF-H2O,120C.(ix)LiOH,THF-H2O,reflux;(x)SOCl2,toluene,reflux;(xi)acetamideoxime,K2CO3,
toluene, reflux; (xii) NH3 (gas), THF.
Scheme 4. Synthesis of Substituted Benzothiazole Derivatives from 3-Cyanomethoxy-2,6-difluoro-benzamide 19 and Substituted
2-aminobenzenethiols
a
aReagents: (ii) chloroacetonitrile, K2CO3, DMF; (xiii) ∼10 N KOH in 2-methoxyethanol or 10 N NaOH, reflux; (xiv) EtOH at 120-150 C.3930 Journal of Medicinal Chemistry, 2010, Vol. 53, No. 10 Haydon et al.
benzothiazoles, two analogues, with 5-chloro or 5-phenyl
substitutions, were found to have improved on target anti-
bacterial activity (8j and 8a) with MICs of 0.25 μg/mL.
Because improved activity was observed for the 5-chloro
and 5-phenyl derivatives, further substitutions in the 5-posi-
tion of the benzothiazole were explored next.
Table 3 summarizes the activity of a set of 5-substituted
benzothiazoles. In contrast to polar substitutions, hydropho-
bic substitutions at the 5-position resulted in improved on-
target activity compared to the unsubstituted benzothiazole.
Derivatives with 5-propyl 11, 5-ethoxy 8b, 5-bromo 8d,a n d
5-trifluoromethyl8esubstitutionsallhavesubmicrogram/mL
Scheme 5. Synthesis of Substituted Benzothiazole Derivatives by Alkylation of 2,6-Difluoro-3-hydoxybenzamide 4 Using Alkyl
Halides (23a-23e)
a
aReagents: (ii) K2CO3, DMF; (xv) 24c,P d -C, NH3 (aq), MeOH.
Scheme 6. Synthesis of Thiazolopyridine Derivatives by Alkylation of 2,6-Difluoro-3-hydoxybenzamide (4) Using Alkyl Halides
(26, 27a-27d)
a
aReagents: (ii) K2CO3, DMF; (xvi) 28a, phenylboronic acid, dichlorobis(triphenylphosphine)palladium(II), K3PO4, DMF-H2O, 110 C; (xvii) 28b,
2,4,6-trifluoro-3-methoxyphenyl boronic acid, K3PO4, dichlorobis(triphenylphosphine)palladium(II), DMF-H2O.
Table 1. S. aureus MICs and Cell Division Inhibitory Activity for Compounds 6a-k
compd R
1 group
S. aureus
MIC (μg/mL)
S. aureus
MIC þ 2% BSA
(μg/mL)
cell division
inhibition
a
(μg/mL) clogP
1 methoxy 2048 4096 WT
b 1.1
6a hexyloxy 8 32 8 3.3
6b (4-methyl-1,3-thiazol-2-yl)methoxy 16 16 16 1.7
6c (5-methyl-1,3-thiazol-2-yl)methoxy 256 256 WT 1.7
6d (2-phenyl-1,3-thiazol-4-yl)methoxy 4 16 4 2.7
6e 2-(1H-pyrazol-1-yl)ethoxy 256 256 WT 1.7
6f 1,3-benzothiazol-2-yl-oxy >256 >256 WT 2.8
6g 1,3-benzothiazol-2-ylmethoxy 2 8 4 2.2
6h quinolin-2-ylmethoxy 16 32 16 2.7
6i 1,3-benzoxazol-2-ylmethoxy 128 256 256 2.3
6j (4-methylthiophen-2-yl)methoxy 32 128 32 2.7
6k (6-methylpyridin-2-yl)methoxy 32 64 32 2.1
aLowest concentration at which ballooningof S. aureusis observedindicating on-target activity. WT: no effect on morphology.
bEnlargedcells, but
not balloons as seen with more potent compounds, were observed at 2048-4096 μg/mL.Article Journal of Medicinal Chemistry, 2010, Vol. 53, No. 10 3931
MICs against S.aureus.S i m i l a r l y ,m e t h y le s t e r( 8i) and 1,2,4-
oxadiazol-5-yl (17) substitutions resulted in improved on-
target activity.
The design of molecules was largely driven by traditional
SAR-directed medicinal chemistry processes; however, the
availability of FtsZ crystal structures enabled the use of
structure-informed optimization of the ligands.
Acleftbetweenhelix7andtheC-terminaldomainofFtsZ
15
was identified as a potential binding site for this series of
inhibitors (Figure 3).
11 The experimental findings described
herein are consistent with the proposed binding model with a
preference for hydrophobic substitutions and all of the active
compounds docked convincingly into the hydrophobic chan-
nel present in the S. aureus FtsZ protein. The model was not
used to design molecules per se, however it was used as a tool
toprioritisethesynthesisof compoundsthatdockedwell into
the binding site.
Because of the hydrophobic nature of the molecules, the
proteinbindingwasofconcernandtheeffectofproteinonthe
antibacterial activity was tracked by adding protein (50% v/v
serum or 2% w/v bovine serum albumin (BSA)) to the MIC
assays.Thealkyloxycompounds,suchas6a,wereparticularly
sensitive to the presence of added protein with serum or BSA
inducing large fold increases in the MICs. The majority of
compounds described herein were less sensitive to added
protein, with serum or BSA inducing more modest shifts in
the MICs (Tables 1 and 4). Nonetheless, the most active
benzothiazole derivatives were still highly bound to protein
with plasma protein binding values of >95% being observed
using an equilibrium dialysis assay (Table 4).
Because hydrophobic substituents appear to be preferred
from anactivity perspective (Table 3), attempts were made to
reduce protein binding by lowering the logP without introdu-
cingpolargroups.Assuch,asetofthiazolopyridineanalogues
were synthesized (Scheme 6). The antibacterial activity and
plasma protein binding were determined for these analogues
(Table 4).
The thiazolopyridine (28c)w h e r eZ
2=N was 32-fold less
active than the benzothiazole (8j), however where Z
1=N(2,
30,a n d29), the antibacterial activity was equivalent or only
2-4-fold less potent than the corresponding benzothiazole.
Furthermore, the plasma protein binding of the thiazolopyri-
dines waslowerforthechloro (2) andethoxy(29)d e r i v a t i v e s .
The in vitro ADME properties were determined for mole-
cules where the potency and protein binding were suitable for
progression. The upper portion of Table 5 summarizes the
resultsofasetofinvitroscreensusedtoevaluatethedrug-like
properties of compound 2 with compound 8j shown for
comparison.Standard deviations areshown, whereavailable,
to illustrate typical assay variability.
Compound 2 did not inhibit any of the cytochrome P450
isozymestested,nordiditinhibitthehERGionchannelatthe
concentrations tested. The chemical and plasma stabilities of
compound2weregood,andtheclearancesinmicrosomesand
hepatocytes werelow, suggestingthatit should not be rapidly
metabolized in vivo. The permeability of compound 2 in
Caco-2 cells was good with a low efflux ratio, indicating that
compound 2 should not be a substrate of drug transporters
such as P-glycoprotein and should be orally bioavailable.
Compound 8j had a similar ADME profile to compound 2,
with increased plasma protein binding and increased clear-
ance in hepatocytes being the notable exceptions.
Table5andFigure4illustratethepharmacokineticproper-
ties of compound 2,w i t h8j shown for comparison. The
clearance (CL) of compound 2 following intravenous admin-
istration in the mouse was low, with a long terminal half-life
(T1/2) resulting in a good area under the curve (AUC). The
oral bioavailability of compound 2 was also good at 57%. In
Table 2. S. aureus MICs and Cell Division Inhibitory Activity for a Set
of Substituted Benzothiazoles
compd
R
2
group
S. aureus
MIC (μg/mL)
cell division
inhibition
a
(μg/mL)
6g 24
22a 4-Cl 16 8
8j 5-Cl 0.25 0.25
22b 6-Cl 4 8
24e 7-Cl 4 8
22c 4-Me 16 2048
8f 5-Me 4 8
22d 6-Me 8 WT
25 4-MeO 16 64
8h 5-MeO 2 2
24b 6-MeO >256 WT
22e 4-Ph >256 WT
8a 5-Ph 0.25 0.5
24a 6-Ph >256 WT
24d 7-Ph >256 WT
aLowest concentration at which ballooning of S. aureus is observed
indicating on-target activity. WT: No effect on morphology.
Table 3. S. aureus MICs and Cell Division Inhibitory Activity for a Set
of 5-Substituted Benzothiazoles
compd
R
3
group
S. aureus
MIC (μg/mL)
cell division
inhibition
a
(μg/mL)
6g 5-H 2 4
8j 5-Cl 0.25 0.25
8f 5-Me 4 8
11 5-propyl 0.125 0.125
8h 5-MeO 2 2
8b 5-EtO 0.125 0.125
8a 5-Ph 0.25 0.5
8d 5-Br 0.125 0.25
8e 5-CF3 0.25 0.5
18 5-OH 32 64
9 5-NH2 >64 WT
8g 5-(dimethylamino) >64 WT
16 5-CONH2 >64 WT
14 5-COOH >64 WT
8i 5-COOMe 1 2
17 5-(1,2,4-oxadiazol-5-yl) 0.5 0.5
13 5-(imidazol-2-yl) >64 WT
aLowest concentration at which ballooning of S. aureus is observed
indicating on-target activity. WT: no effect on morphology.3932 Journal of Medicinal Chemistry, 2010, Vol. 53, No. 10 Haydon et al.
contrast,thecorrespondingbenzothiazole(compound8j)was
rapidly cleared both in hepatocytes and in the mouse.
Both compounds 2 and 8j were tested in a murine model of
staphylococcalinfection(Figure5).Compound2wasefficacious
following a single administration: intraperitoneal (IP) ED50 <
3 mg/kg, subcutaneous (SC) ED50=7 mg/kg, and intravenous
(IV) ED50 =1 0m g / k g .
11 While compound 8j was efficacious
whenadministeredIP(ED50=41mg/kg),itwasnotwhenadmi-
nistered SC (ED50>30 mg/kg). Although the bioavailability of
compound 2 was good, no efficacy was observed following a
single oral administration of 30 mg/kg (data not shown).
Therefore the modest reduction in potency of the thiazolo-
pyridinecomparedtothebenzothiazoleismorethanoffsetby
reducingproteinbindingandmetabolism,resultinginadrug-
likepharmacokineticprofileandefficacyinthemurinemodel
of staphylococcal infection.
Conclusion
A series of 3-substituted benzamides as inhibitors of FtsZ,
which demonstrate potent antistaphylococcal activity by
inhibiting cell division, has been synthesized and the SAR
has been determined.
Replacement of a 3-alkyloxy substituent with a variety of
heteroarylmethoxy substituents resulted in drug-like com-
pounds with on-target antibacterial activity. The most potent
of these substitutions was 1,3-benzothiazol-2-ylmethoxy,
so the focus was to optimize the benzothiazole by fur-
ther substitution around the phenyl ring. Substitutions such
as chloro, phenyl, or ethyloxy in the 5-position of the ben-
zothiazole resulted in an 8- to 16-fold improvement in the
on-target activity, with MICs as low as 0.125 μg/mL against
S. aureus.
Although these 5-substituted-1,3-benzothiazol-2-ylmethoxy
compounds were more drug-like than the 3-alkyloxy deriva-
tives described above, their protein binding, at >95% bound
toplasma,wasconsideredtoohightoprogress.Replacingthe
benzothiazolesubstituentwithathiazolopyridinereducedthe
antibacterial activity but also reduced the plasma protein
binding. Furthermore, the metabolic stability of the thiazolo-
pyridinewasimprovedcomparedtothebenzothiazole,resulting
Figure 3. Model of 2 docked into cleft of FtsZ. Close up view showing the nucleotide substrate bound into the nucleotide-binding site (right)
and2dockedintoacleft(left)analogoustothetaxol-bindingsiteoftubulinadjacenttohelix7(red).Inthismodel,hydrogenbondsareformed
between the phenoxy ether of 2 and R191 and Q192 (dashed yellow lines).
Table 4. S. aureus MICs and Plasma Protein Binding for a Series of Substituted Benzothiazoles and Thiazolopyridines
compd R
4 Z
1 Z
2
S. aureus
MIC (μg/mL)
S. aureus
MIC þ 2% BSA
(μg/mL)
plasma protein
binding
a
(% bound) clogP
8j Cl CH CH 0.25 2 96.4 2.5
2 Cl N CH 1 2 85.4 1.4
8a Ph CH CH 0.25 4 99.2 3.4
30 Ph N CH 0.5 4 98.5 2.4
8b EtO CH CH 0.125 0.5 96.4 1.9
29 EtO N CH 0.125 0.25 89.9 0.9
28c Cl CH N 8 32 nd 1.4
28d MeO N CCl 16 >64 nd 0.9
aPercent of compound bound to mouse plasma. nd: not determined.Article Journal of Medicinal Chemistry, 2010, Vol. 53, No. 10 3933
in an approximately 15-fold reduction in clearance following
intravenous administration in the mouse.
The balance of antibacterial activity, plasma protein bind-
ing, and metabolic stability of compound 2 resulted in the
compound being tested in themousemodel ofstaphylococcal
infection. Compound 2 was efficacious in an in vivo model
of infection, protecting mice infected with a lethal dose of
S. aureus. The data validate FtsZ as a target for antibacterial
intervention and demonstrate that the series is suitable for
optimization into a new antistaphylococcal therapy.
Experimental Section
Antimicrobial Testing. S. aureus ATCC 29213 was obtained
from LGC Promochem (Teddington, UK) and was propagated
according to standard microbiological practice. MICs were
determined by the broth microdilution method according to
the recommendations of the Clinical andLaboratory Standards
Institute.
16 Cell division phenotype assays were performed as
described previously.
17
ADME Testing. The cytochrome P450 assay measured the
metabolism of fluorogenic substrates by human recombinant
enzymessuppliedbyInvitrogen.ThehERGassay,performedat
CyprotexLtd.(Macclesfield,UK),wasasinglecellplanarpatch
clamp assay. Plasma protein binding was assessed by equilibri-
um dialysis of a 10 μM solution using the Pierce RED devices.
Plasma stability of a 10 μM solution was determined by LC/MS
after24hat37C.Microsomalstabilityofa10μMsolutionwas
determined over a time course by measuring the remaining
parent compound using LC/MS. Permeability assays, per-
formed at Cyprotex Ltd., used LC/MS/MS to determine bidir-
ectionaltransportacrossCaco-2monolayers.Chemicalstability
ofa10μMsolutioninphosphatebufferedsalinewasdetermined
by LC/MS after 24 h at 37 C. Hepatocyte stability of a 10 μM
solution, performed at Cyprotex Ltd., was determined over a
timecoursebymeasuringtheremainingparentcompoundusing
LC/MS/MS.
Pharmacokinetics. Parameters were calculated using Win-
Nonlin from the plasma concentrations determined by LC/
MS/MS over an 8 h time course following intravenous or oral
administration of the compounds in mice.
Efficacy. Mice were inoculated IP with an LD90-100 of
S. aureus (Smith) (5 10
5 CFU/mouse for SC study and 4  
10
5 CFU/mouse for IP study) in 0.5 mL of brain heart infu-
sion broth containing 5% mucin. Vehicle and test substances
were administered SC or IP 1 h after bacterial inoculation.
Mortality was monitored for 7 days. The minimal effective dose
(ED50) was determined by nonlinear regression using Graph
Pad Prism.
Ligand Docking. Docking of ligands to the putative bind-
ing site on Bacillus subtilis FtsZ described previously
11 was
completed usingBenchware 3D Explorer software (Tripos L.P.).
clogP Calculations. clogP was calculated using Accord for
Excel (Accelrys Sofware Inc.).
Experimental Procedures. All nonaqueous reactions were
carried out under nitrogen atmosphere. Reagents and solvents
Table 5. ADME Properties and PK Parameters for Compounds 2 and 8j
a
assay units 8j 2
CYP1A2 inhibition IC50 (μg/mL) >12 >12
CYP2C19 inhibition IC50 (μg/mL) >12 >12
CYP2C9 inhibition IC50 (μg/mL) >12 >12
CYP2D6 inhibition IC50 (μg/mL) >12 >12
CYP3A4 inhibition IC50 (μg/mL) >12 >12
chemical stability % remaining after 24 h 99 ( 5.4 100 ( 10.3
human microsomal stability CL (μL/min/mg) nd 7.2 ( 4.4
human plasma stability % remaining after 24 h nd 100 ( 5.2
human plasma binding fraction unbound 0.01 ( 0.01 0.10 ( 0.03
mouse hepatocyte stability CL (μL/min/10
6cells) 31.2 ( 2.7 9.51 ( 1.6
mouse microsomal stability CL (μL/min/mg) 14.0 ( 4.8 14.5 ( 10.3
mouse plasma stability % remaining after 24 h 99 ( 11.2 94 ( 10.8
mouse plasma binding fraction unbound 0.03 ( 0.02 0.15 ( 0.06
hERG inhibition IC50 (μM) nd >10
Caco-2 permeability efflux ratio nd 0.645
Caco-2 permeability PappAB (cm/s) nd 48.7
Caco-2 permeability PappBA (cm/s) nd 31.4
mouse intravenous PK parameters dose (mg/kg) 2 3 [3]
[mouse oral PK parameters] AUC (μg3h/mL) 0.1 2.42 [1.39]
C0 [Cmax]( μg/mL) 0.5 3.7 [0.7]
CL (mL/min/kg) 315 20.6
T1/2 [Tmax] (min) 13 37 [24]
V (L/kg) 5.8 1.06
and: not determined. ( standard deviations.
Figure 4. Pharmacokineticprofileofcompounds2(solidlines)and8j
(dotted line). Compound 2 was dosed intravenously (black line) and
orally (gray line) at 3 mg/kg individually and compound 8j at 2 mg/kg
in a cassette. Plasma concentrations were measured over an 8 h period
with samples taken after 5, 15, 30, 60, 120, 240, and 480 min.3934 Journal of Medicinal Chemistry, 2010, Vol. 53, No. 10 Haydon et al.
were obtained from commercial sources and were used without
further purification. 2,6-Difluoro-3-methoxybenzamide (3) was
purchased from JRD Fluorochemicals Ltd. Yields refer to puri-
fied products and are not optimized. Analytical TLC was
performed on Merck silica gel 60 F254 aluminum-backed plates.
Compounds were visualized by UV light and/or stained with
either I2 or potassium permanganate solution followed by
heating.Flashcolumnchromatographywasperformedonsilica
gel.
1H NMR spectra were recorded on either a JEOL GSX-400
MHz or on a Bruker Avance 400 MHz spectrometer with a
Broad Band Observe (BBO) and Broad Band Fluorine Observe
(BBFO) probe. Chemical shifts (δ) are expressed in parts per
million(ppm)downfieldbyreferencetotetramethylsilaneasthe
internalstandard.Splittingpatternsaredesignatedass(singlet),
d (doublet), t (triplet), q (quartet), m (multiplet), br s (broad
singlet), app (apparent). Coupling constants (J) are given in
hertz (Hz). LC-MS analyses were performed on either an
Acquity C-18 column (2.10 mm 100 mm, 1.70 μm) using the
electrospray ionization (ESI) technique or on a Gemini C-18
column (4.6mm  50 mm, 5 μm)using theatmospheric pressure
chemical ionization (APCI) technique. The purity of all tested
compounds was determined by analytical HPLC and HPLC-
MSanalysesandwasgreaterthan95%,unlessotherwisestated.
Purityassessment forfinalcompoundswasbasedonthefollow-
ing 5 HPLC methods. Method 1 consisted of the following:
Discovery HSC-18 column 4.60 mm   250 mm, 5 μm. Mobile
phase; A, acetonitrile with 0.10% formic acid; B, H2O with
0.10% formic acid; gradient, 10% A to 90% A in 15 min with
30minruntimeandaflowrateof1mL/min.Method2consisted
of the following: Purospher Star C-18 column 4.60 mm 250 mm,
5 μm. Mobile phase; A, acetonitrile with 0.10% formic acid; B,
H2Owith0.10%formicacid;gradient,10%Ato90%Ain15min
with30minruntimeandaflowrateof1mL/min.Method3con-
sisted of the following: Xbridge C-18 column 4.60 mm 250 mm,
5 μm. Mobile phase; A, acetonitrile with 0.10% formic acid; B,
H2Owith0.10%formicacid;gradient,10%Ato90%Ain15min
with 30 min run time and a flow rate of 1 mL/min. Method 4
consisted of the following: Acquity BEH C-18 column 2.10 mm
 100 mm, 1.70 μm. Mobile phase; A, acetonitrile with 0.10%
formicacid;B,H2Owith0.10%formicacid;gradient,10%Ato
90% A in 6 min with 10 min run time and a flow rate of 1 mL/
min. Method 5 consisted of the following: Gemini C-18 column
4.6mm 50mm,5μm.Mobilephase:20-90%CH3CN:10mM
aqueous ammonium acetate, over 4 min, isocratic for 1 min,
20% CH3CN:10 mM aqueous ammonium acetate for 2 min,
flow rate=1 mL/min at 40 C. Melting points were measured
using a Stuart Scientific SMP10 or a Buchi B545 apparatus and
areuncorrected.Experimentalandspectroscopicdetailsofcom-
pounds not described herein and synthetic schemes and experi-
mental details of the intermediates used to make all compounds
are presented in the Supporting Information.
2,6-Difluoro-3-hydroxybenzamide(4).Borontribromidesolu-
tion (1 M in CH2Cl2, 8.55 mL, 8.55 mmol, 2 equiv) was added
dropwise to a stirred suspension of 2,6-difluoro-3-methoxyben-
zamide (3) (800 mg, 4.3 mmol) in CH2Cl2 (20 mL), at room
temperature, under N2 atmosphere. The reaction mixture was
stirred at room temperature for 48 h. The solvent was removed
under reduced pressure, and the residue was taken up in water
(50 mL) and extracted with EtOAc (3 40 mL). The combined
organic extracts were washed with water (2   40 mL), dried
(Na2SO4),andfilteredthroughapadofsilica.Thefiltratewaseva-
porated to dryness under reduced pressure, to give 4 as a light-
brown solid (580 mg, 78%).
1H NMR (DMSO-d6): δ 6.90-6.95
(m, 2H), 7.73 (br s, 1H), 8.03 (br s, 1H), 9.89 (br s, 1H).
2-(Benzyloxy)-N-(2,5-dichloropyridin-3-yl)acetamide (32). To
an ice-cold solution of 2,5-dichloropyridin-3-amine (31) (2.50 g,
15.33mmol) inCH2Cl2(50mL) wasaddedtriethylamine(3.17mL,
23 mmol, 1.5 equiv) followed by the addition of a solution of
2-(benzyloxy)acetyl chloride (4.20 g, 23 mmol, 1.5 equiv) in
CH2Cl2 (50 mL). The resulting mixture was stirred at room
temperature for 2 h. The solvent was removed under reduced
pressure, and the residue was taken up in water (100 mL) and
extracted with EtOAc (3   100 mL). The combined organic
extracts were washed with brine, dried (Na2SO4), filtered, and
Figure 5. Efficacyofcompounds2and8jinthemurinesepticaemiamodelofstaphylococcalinfection.(A,C) Compound8j,(B,D)compound
2. (A,B) Subcutaneous (SC) administration, (C,D) intraperitoneal (IP) administration. Solid lines = 30 mg/kg, dashed lines = 10 mg/kg,
dotted lines = 3 mg/kg. All mice treated with vehicle alone died on day 2. All mice treated SC with 3, 10, or 30 mg/kg of compound 8j died on
day 2 (A). All mice treated IP with 3, 10, or 30 mg/kg of compound 2 survived (D).Article Journal of Medicinal Chemistry, 2010, Vol. 53, No. 10 3935
concentrated under reduced pressure. The residue was puri-
fied over silica eluting with 5% EtOAc-hexane to obtain
the title compound 32 (2.20 g, 46%). LCMS (ESI) 311.04
[M þ H]
þ, 84%.
2-[(Benzyloxy)methyl]-6-chloropyrido[3,2-d][1,3]thiazole (33).
To a solution of 32 (2.20 g, 7.07 mmol) in toluene (50 mL) was
added Lawesson’s reagent (2.84 g, 7.07 mmol, 1 equiv), and the
resulting reaction mixture was refluxed for 4-5 h. The solvent
was evaporated and the residue was purified over silica eluting
with 3% EtOAc-hexane to obtain the title compound 33 (1.75 g,
85%). LCMS (ESI) 291.18 [M þ H]
þ, 87.50%.
2-(Bromomethyl)-6-chloropyrido[3,2-d][1,3]thiazole(26,Scheme7).
Asolutionof33(2g,6.87mmol)inCH2Cl2(100mL)wascooled
to -78 C followed by dropwise addition of BBr3 (3.30 mL,
34.39 mmol, 5 equiv). The mixture was stirred at room tem-
perature for 3 h then was cooled again to -78 C and quenched
by dropwise addition of water followed by extraction with
EtOAc (3   100 mL). The combined organic extracts were
washed with saturated NaHCO3 solution, dried (Na2SO4), filte-
red, and concentrated under reduced pressure. The residue was
purified over silica eluting with 2% EtOAc-hexane to obtain
the title compound 26 (1.50 g, 88%).
1H NMR (DMSO-d6): δ
5.16 (s, 2H), 8.67 (d, J=2.4 Hz, 1H), 8.73 (d, J=2.4 Hz, 1H).
MS (ESI) m/z: 262.90 [M þ H]
þ.
General Procedure for the Alkylation of 4 Using Alkyl or
Arylmethyl Halides. K2CO3 (1.5-3.5equiv) andNaI (0.2equiv)
were added to a solution of 4 in DMF (3-8 mL per mmol). The
resulting suspension was stirred for 5 min at room temperature
beforethecorrespondinghalide(1.0-1.1equiv)wasadded.The
reaction mixture was stirred at 20-60 C for 3-18 h, under N2
atmosphere. After cooling to room temperature, one of two
workup procedures was followed. In some cases, the reaction
mixture was poured into water (15 mL per mmol), and the
precipitant solid was filtered, washed with water, and dried to
give the crude product. In other cases, the reaction mixture was
partitionedbetweenEtOAc(30mLpermmol)andwater(20mL
per mmol), the organic phase was separated, washed with water
(2 15 mL), dried (MgSO4), filtered, and concentrated in vacuo
to give the crude solid.
3-({6-Chloropyrido[3,2-d][1,3]thiazol-2-yl}methoxy)-2,6-difluoro-
benzamide (2). Compound 2 was prepared from 4 (590 mg, 3.41
mmol) and 26 (900 mg, 3.41 mmol, 1 equiv) using 3.5 equiv of
K2CO3, according to the general procedure (20 C, 3 h, EtOAc/
H2O workup). The residue was purified over silica eluting with
60% EtOAc-hexane to obtain the title compound 2 (940 mg,
78%),mp218C.
1HNMR(DMSO-d6):δ5.72(s,2H),7.12(m,
1H), 7.40 (m, 1H), 7.89 (br s, 1H), 8.17 (br s, 1H), 8.68 (d, J=
2.4 Hz, 1H), 8.73 (d, J = 2.4 Hz, 1H). MS (ESI) m/z 356.27
[M þ H]
þ. HPLC (method 3) Rt=15.40 min.
3-(Cyanomethoxy)-2,6-difluorobenzamide (19). Compound 19
was prepared from 4 (1 g, 5.8 mmol) and chloroacetonitrile
(0.40 mL, 6.4 mmol, 1.1 equiv) using 1.5 equiv K2CO3, according
to the general procedure (60 C, overnight, EtOAc/H2O workup).
The crude product was triturated with diethyl ether (30 mL),
filtered, and dried in vacuo to give 19 a sag r a ys o l i d( 1 . 0 6g ,
86%); mp 122-123 C.
1HN M R(D MS O - d6):δ5.26 (s, 2H), 7.18
(app dt, J=9.0, 1.8 Hz, 1H), 7.40 (m, 1H), 7.86 (br s, 1H), 8.14
(brs,1H).HPLC-MS(APCI)m/z213[MþH]
þ,(method5) Rt=
1.97 min.
General procedure for the synthesis of substituted benzothia-
zole derivatives from 3-cyanomethoxy-2,6-difluoro-benzamide
(19) andsubstituted1,3-benzothiazol-2-amines.AsolutionofKOH
(20 equiv) in water (25 mL) was added to a solution of the sub-
stituted 1,3-benzothiazol-2-amine in 2-methoxy-ethanol (25 mL),
and the reaction mixture was heated to reflux overnight. After
coolingatroomtemperature,themixturewasdilutedwithwater
(200mL),acidifiedwith5NHClsolutiontopH4,andextracted
with CH2Cl2 (3 150 mL). The combined organic extracts were
washed with brine (100 mL), dried (Na2SO4), and concentrated
under reduced pressure to dryness, to give crude substituted
2-aminobenzenethiol.Aportionofthismaterial(1.5equiv)were
mixedwith19(150mg,0.7mmol),andthemixturewasstirredat
120 C, in a preheated oil bath, under N2, for 2 h. EtOH (2 mL)
was added and the reaction mixture was heated at 120 C for a
further 2 h. The products either precipitated from the reaction
mixture on cooling or the reaction mixtures were evaporated
andthecrudeproductspurifiedbytriturationoftheresidue.See
the Supporting Information for exact details of each example.
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